WO2009137505A3 - Anti-inflammatory mirnas and uses therefor - Google Patents

Anti-inflammatory mirnas and uses therefor Download PDF

Info

Publication number
WO2009137505A3
WO2009137505A3 PCT/US2009/042880 US2009042880W WO2009137505A3 WO 2009137505 A3 WO2009137505 A3 WO 2009137505A3 US 2009042880 W US2009042880 W US 2009042880W WO 2009137505 A3 WO2009137505 A3 WO 2009137505A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
subject
modulating
uses therefor
expression
Prior art date
Application number
PCT/US2009/042880
Other languages
French (fr)
Other versions
WO2009137505A2 (en
Inventor
Denis F. Kinane
Manjunatha R. Benakanakere
Original Assignee
University Of Louisville Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Louisville Research Foundation, Inc. filed Critical University Of Louisville Research Foundation, Inc.
Publication of WO2009137505A2 publication Critical patent/WO2009137505A2/en
Publication of WO2009137505A3 publication Critical patent/WO2009137505A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

The presently disclosed subject matter relates to methods and compositions for detecting and for modulating expression of gene products associated with control of innate immune responses. In some embodiments, the methods include expressing in a cell a recombinant expression vector that encodes a microRNA (miRNA) in an amount sufficient to modulate expression of a Toll-like Receptor 2 (TLR2) gene product. Also provided are methods for modulating growth of Porphyromonas gingivalis in a subject, and for predicting a predisposition of a subject to develop an oral bacteria infection.
PCT/US2009/042880 2008-05-05 2009-05-05 Anti-inflammatory mirnas and uses therefor WO2009137505A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12643208P 2008-05-05 2008-05-05
US61/126,432 2008-05-05

Publications (2)

Publication Number Publication Date
WO2009137505A2 WO2009137505A2 (en) 2009-11-12
WO2009137505A3 true WO2009137505A3 (en) 2010-03-11

Family

ID=41009972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/042880 WO2009137505A2 (en) 2008-05-05 2009-05-05 Anti-inflammatory mirnas and uses therefor

Country Status (1)

Country Link
WO (1) WO2009137505A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694533A (en) * 2013-12-09 2015-06-10 江苏命码生物科技有限公司 Non-coding RNA (ribonucleic acid) of salmonella as well as identification and application of non-coding RNA
US10113170B2 (en) 2014-07-24 2018-10-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Preventing and treating inflammatory skin diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164172A1 (en) * 2004-01-22 2005-07-28 Kurt-Jones Evelyn A. Modulation of HSV infection
US20060058255A1 (en) * 2004-03-01 2006-03-16 Jianzhu Chen RNAi-based therapeutics for allergic rhinitis and asthma
US20070232553A1 (en) * 2006-03-23 2007-10-04 California Institute Of Technology MODULATION OF INNATE IMMUNITY RECEPTORS' SIGNALING BY microRNAs miR-146a AND miR-146b

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164172A1 (en) * 2004-01-22 2005-07-28 Kurt-Jones Evelyn A. Modulation of HSV infection
US20060058255A1 (en) * 2004-03-01 2006-03-16 Jianzhu Chen RNAi-based therapeutics for allergic rhinitis and asthma
US20070232553A1 (en) * 2006-03-23 2007-10-04 California Institute Of Technology MODULATION OF INNATE IMMUNITY RECEPTORS' SIGNALING BY microRNAs miR-146a AND miR-146b

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BENAKANAKERE MANJUNATHA R; LI QIYAN; ESKAN MEHMET A; SINGH AMAR V; ZHAO JIAWEI; GALICIA JOHNAH C; STATHOPOULOU PANAGIOTA; KNUDSEN: "Modulation of TLR2 Protein Expression by miR-105 in Human Oral Keratinocytes.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 21 AUG 2009, vol. 284, no. 34, 9 June 2009 (2009-06-09), pages 23107 - 23115, XP002544552, ISSN: 0021-9258 *
ESKAN MEHMET A; BENAKANAKERE MANJUNATHA R; ROSE BEATE G; ZHANG PING; ZHAO JIAWEI; STATHOPOULOU PANAGIOTA; FUJIOKA DAISUKE; KINANE: "Interleukin-1beta modulates proinflammatory cytokine production in human epithelial cells.", INFECTION AND IMMUNITY MAY 2008, vol. 76, no. 5, 10 March 2008 (2008-03-10), pages 2080 - 2089, XP002544548, ISSN: 1098-5522 *
KINANE DENIS F; GALICIA JOHNAH CORTEZ; GORR SVEN-ULRIK; STATHOPOULOU PANAGIOTA GIORGIOS; BENAKANAKERE MANJUNATHA: "P. gingivalis interactions with epithelial cells", FRONTIERS IN BIOSCIENCE, vol. 13, January 2008 (2008-01-01), pages 966 - 984, XP002544551, ISSN: 1093-9946 *
LINDSAY; M A: "microRNAs and the immune response", TRENDS IN IMMUNOLOGY, ELSEVIER, RAHWAY, NJ, US, vol. 29, no. 7, 1 July 2008 (2008-07-01), pages 343 - 351, XP022765475, ISSN: 1471-4906, [retrieved on 20080624] *
MOSCHOS STERGHIOS A; WILLIAMS ANDREW E; PERRY MARK M; BIRRELL MARK A; BELVISI MARIA G; LINDSAY MARK A: "Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids", BMC GENOMICS, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 1, 17 July 2007 (2007-07-17), pages 240, XP021028054, ISSN: 1471-2164 *
O'CONNELL RYAN M; TAGANOV KONSTANTIN D; BOLDIN MARK P; CHENG GENHONG; BALTIMORE DAVID: "MicroRNA-155 is induced during the macrophage inflammatory response", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 5, January 2007 (2007-01-01), pages 1604 - 1609, XP002544550, ISSN: 0027-8424 *
SONKOLY; STAHLE E; PIVARCSI M; A: "MicroRNAs and immunity: Novel players in the regulation of normal immune function and inflammation", SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC PUBLICATIONS, PHILADELPHIA, PA, US, vol. 18, no. 2, 15 January 2008 (2008-01-15), pages 131 - 140, XP022517942, ISSN: 1044-579X *
TAGANOV KONSTANTIN D; BOLDIN MARK P; CHANG KUANG-JUNG; BALTIMORE DAVID: "NF-kappa B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 103, no. 33, August 2006 (2006-08-01), pages 12481 - 12486, XP002544549, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2009137505A2 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
WO2008119082A3 (en) Enhanced production of fatty acid derivatives
MX343604B (en) Decreasing lactate level and increasing polypeptide production by downregulating ldh and pdhk expression.
AU2009209251A8 (en) Stabilized Angiopoietin-2 antibodies and uses thereof
GB2459756B (en) Enhanced ABE fermentation with high yielding butanol tolerant Clostridium strains
WO2010048417A3 (en) Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products
MX2009013188A (en) Methods for producing fermentation products.
WO2011057248A3 (en) Methods of propagating monkey adenoviral vectors
WO2011113030A3 (en) Human cancer micro-rna expression profiles predictive of chemo-response
WO2010089151A8 (en) Bioreactor for the cultivation of mammalian cells
SG181422A1 (en) Microbial engineering for the production of chemical and pharmaceutical products from the isoprenoid pathway
EA201491848A1 (en) BIOSAFETY USING LACTOBACILLUS PARACASEI STRAINS
WO2009027830A3 (en) Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
WO2010014631A3 (en) Methods and compositions for improving the production of products in microorganisms
WO2013039776A8 (en) Methods of hydrolyzing and fermenting cellulosic material
WO2010068897A3 (en) Stem cell enhanced protein products and uses thereof
MX2016008208A (en) Process for extracting lipids for use in production of biofuels.
WO2014093505A3 (en) Acp-mediated production of fatty acid derivatives
WO2009102569A3 (en) Cell lines and methods for making and using them
WO2012003402A3 (en) Compositions and methods for culturing microorganisms
WO2012135591A3 (en) Microbial isoprenoid production using a heterologous dxp pathway
WO2011029013A3 (en) Production of secreted bioproducts from photosynthetic microbes
EP3666900A3 (en) Cell-based production of nonulosonates
WO2013141905A3 (en) Engineering an increase in ethanol production by altering cofactor specificity
WO2011060044A8 (en) Methods for microbial production of terpenoids
EP4282972A3 (en) Production of branched chain fatty acids and derivatives thereof in recombinant microbial cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09743491

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09743491

Country of ref document: EP

Kind code of ref document: A2